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Background: Despite recent advances in cancer therapeutics in general, the survival of patients with head and
neck squamous cell carcinomas (HNSCCs) has not improved substantially over the past few decades. HNSCC cells
often exhibit invasive and metastatic phenotypes, and expression of epidermal growth factor receptor (EGFR) and
cortactin has been highly implicated in the development of malignancy in HNSCCs. We have shown previously that
an Arf6 pathway, in which Arf6 is activated by GEP100 and employs AMAP1 (also called DDEF1 or ASAP1) as its
downstream effector, is pivotal for the invasion and metastasis of different breast cancer cells. This pathway is
activated by receptor tyrosine kinases, including EGFR; and moreover, AMAP1 physically associates with cortactin, in
which inhibition of this binding effectively blocks invasion and metastasis. We here investigated whether the
expression of Arf6 pathway components correlates with the poor prognosis of HNSCC patients. We have shown
previously that AMAP1 protein levels are not correlated with its mRNA levels, and hence we here employed
immunohistochemical staining of HNSCC clinical specimens to investigate AMAP1 protein levels.
Results: We found that high levels of AMAP1 protein expression on its own, as well as its co-overexpression with
EGFR statistically correlates with poor disease-free survival and poor overall survival, while high levels of cortactin
expression or its co-expression with EGFR did not.
Conclusion: Our identification of predictive biomarkers, together with our previous findings on the coherent
signaling pathway that these biomarkers ultimately generate should be powerful information for the further
development of HNSCC therapeutics.
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Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer in the world [1]. There
are about 500,000 new HNSCC cases reported annually
worldwide [1]. Molecular studies have shown that ag-
gressive HNSCCs frequently have mutations in the TP53
gene, and show high levels of expression of cyclin D1
and epidermal growth factor receptor (EGFR) [2-6].
EGFR and its signaling, as well as high expression levels
of cortactin, have been highly implicated in the* Correspondence: sabeh@med.hokudai.ac.jp
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unless otherwise stated.aggressiveness of HNSCCs and the poor prognosis of pa-
tients [7-10]. Accordingly, Cetuximab, a monoclonal
antibody against EGFR, has been commonly used to
treat recurrent HNSCCs, by itself or in combination
with platinum-based cytotoxic agents [11,12]. However,
the therapeutic effects of Cetuximab are not uniform,
and moreover, most recurrent HNSCCs eventually ac-
quire resistance to such treatments using antibodies and
chemicals. Other types of cancers like lung cancer often
bear mutations within the EGFR gene [13-15], and colon
cancer often exhibits mutations in the k-ras gene, which
acts downstream of EGFR. These mutations may evoke
resistance to the EGFR-based agents [16]. However, mu-
tations in the EGFR and k-ras genes have been shown tod. This is an Open Access article distributed under the terms of the Creative
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analyses using next-generation sequencers have also re-
vealed rare alterations in these genes in HNSCCs [18].
Moreover, with regard to EGFR and its signaling, previous
studies by other research groups have primarily focused
on the classical components, such as Ras, Raf, Erks, phos-
phatidylinositol 3-kinase, Akt and STAT-3 [19].
We have identified previously another signaling path-
way under EGFR, which mediates invasive and motile
phenotypes of cancer cells. We have shown that an Arf6
pathway, in which Arf6 is activated by GEP100, a guan-
ine nucleotide exchanging factor (GEF) for Arf-GTPases,
and employs AMAP1 (also called DDEF1 or ASAP1) as
its downstream effector, is pivotal for the invasion and
metastasis of different breast cancer cells [20-25]. In this
Arf6 pathway, GEP100, via its PH domain, physically as-
sociates with tyrosine phosphorylated EGFR to activate
Arf6 at the plasma membrane [23]. Both the Arf6 and
AMAP1 proteins are abnormally overexpressed in
highly-invasive breast cancer cell lines, while their ex-
pression is minimal in weakly- and non-invasive breast
cancer cell lines and also in a primary culture of normal
mammary epithelial cells [20,21]. Therefore, this Arf6
pathway appears to be specific to some cancer cells, and
may not normally be used in normal cells. Studies on
clinical specimens of breast cancer revealed that high ex-
pression levels of the AMAP1 protein as well as the co-
overexpression of GEP100 with EGFR correlate well with
their malignant and invasive phenotypes [21,23]. We
have moreover shown previously that expression levels
of the Arf6 and AMAP1 proteins do not correlate with
their mRNA levels [20,21], suggesting that the over-
expression of these proteins are not simply a result of
the over-expression of their mRNAs. This may be the
major reason why these proteins and their genes have
not been identified to correlate with the invasive and
malignant phenotypes of breast cancers by previous gene
expression profiling analyses.
As for the molecular mechanisms of the Arf6 pathway
in invasion, we have shown previously that activation of
Arf6 by GEP100, but not by other GEFs, perturbs E-
cadherin-based cell-cell adhesion of breast cancer cells
and may hence induce their motile phenotypes [23]. On
the other hand, AMAP1 has multiple protein-interacting
modules and can directly interact with different proteins,
including protein kinase D2 (PRKD2) and cortactin.
AMAP1, via its binding to PRKD2, makes a complex
with β1 integrins, in order to mediate the recycling of β1
integrins, leading to cell invasion [24]. Interaction of
AMAP1 with cortactin is also crucial for invasion and
metastasis, in which we have shown that blockage of this
binding by a cell-permeable peptide, namely P4-TAT, ef-
fectively blocks breast cancer invasion in vitro and me-
tastasis in vivo [22].We here investigated whether protein expression of
Arf6 pathway components, as well as EGFR and cortac-
tin, exhibits clinical relevance to the malignant pheno-
types of HNSCCs, with the aim to investigate whether
components of the Arf6 pathway could be predictive
biomarkers and therapeutic targets.
Results
High expression levels of AMAP1 correlate with poor
prognosis
To investigate whether the increased expression of cer-
tain proteins is associated with disease-free survival as
well as overall survival of HNSCC patients after curative
resection of the primary sites, we classified patients
(Table 1) into two groups based on the results of immu-
nohistochemical stainings.
The median H scores for HNSCCs were found to be
0.65 (EGFR), 0.6 (GEP100), 0.3 (AMAP1) and 0.3 (cor-
tactin) (Figure 1A-D, also see Materials and methods).
Tumors with scores above the median H value were
classified into the high expression group, and those
below the median H value were classified into the low
expression group. We found that the 60-month disease-
free survival for patients in the high AMAP1 expression
group is 0%, while it is 42% for those in the low AMAP1
expression group (p = 0.025, Figure 2E). On the other
hand, there were no significant differences in expression
of EGFR, GEP100 or cortactin with regard to the 60-
month disease-free survival (Figure 2A, C and G).
We next analyzed the overall survival of patients. The
60-month overall survival of patients in the high AMAP1
expression group was 0%, while it was 67% for patients in
the low AMAP1 expression group (p < 0.001, Figure 2F).
The 60-month overall survival of the patients in the high
EGFR expression group was 20%, while it was 78% for pa-
tients in the low EGFR expression group (p = 0.028,
Figure 2B). There were no significant differences in sur-
vival rates between groups with different expression levels
of GEP100 as well as groups with different expression
levels of cortactin (Figure 2D and H).
Co-expression of EGFR and AMAP1 both at high levels
correlates with poor prognosis
We then analyzed whether high-level expression of a
combination of these proteins exhibits greater differ-
ences in disease-free survival and overall survival com-
pared with the high expression of each single protein.
Due to the relatively small number of clinical samples in
our hospital, we could only analyze combinations of two
different proteins with statistical significance, but not
the combinations of more than three proteins. We found
that the EGFR/AMAP1 'Homo' group, in which expres-
sions of EGFR and AMAP1 both belong to the high-
expression groups, shows a shorter time to events after
Table 1 Clinicopathologic and characteristics of patients






















Well differentiated 2/20 (60)
Moderately differentiated 7/20 (35)







Clinical specimens were selected from patients undergoing surgical resection
for head and neck squamous cell carcinoma. The tumor site was the oral
cavity (tongue) in all patients.
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of the AMAP1 expression or the EGFR expression, or
both belong to the low-expression groups (p = 0.012 for
the disease-free survival and p < 0.001 for the overall
survival, Figure 3C and D). This difference in the
disease-free survival was greater than that for EGFR
alone and AMAP1 alone, and the difference in the over-
all survival was greater than that for EGFR alone. The
GEP100/AMAP1 'Homo' group, in which expressions of
GEP100 and AMAP1 both belong to the high-
expression groups, also shows a statistically shorter time
to events after HNSCC resection than the 'Others', in
which either one of the GEP100 expression or theAMAP1 expression, or both belong to the low-
expression groups (p = 0.03615 for the disease-free sur-
vival and p < 0.001 for the overall survival, Figure 3G
and H). This difference was, however, not greater than
that for AMAP1 alone. We also examined other combi-
nations, and found that none of them exhibit a statistical
difference with regard to disease-free survival and overall
survival (Figure 3A, B, E, F, I-L).
Discussion
Despite the recent advances in cancer therapeutics, the
overall survival of HNSCC patients after the curative re-
section of tumors has not improved significantly over
the past few decades [26,27]. Among the many different
factors that contribute to poor survival and poor prog-
nosis, the major cause is believed to be the invasive and
metastatic properties of some HNSCCs, which are still
far from under clinical control. Interestingly, HNSCCs
show the highest frequency of high EGFR expression
levels among all different types of cancers, and hence
EGFR-targeted therapies are expected to exhibit benefi-
cial effects [6-8]. Indeed, combination of Cetuximab with
platinum-based chemotherapies, as well as with conven-
tional radiotherapy have been shown to improve the
disease-free survival rates of HNSCC patients, while
these therapies still do not significantly improve their
overall survival [9,12,28]. Inhibition of the downstream
signaling components of EGFR, such as Erks and Akt,
was also thought to be a candidate to block tumor
growth, but this greatly affects the survival and functions
of most normal cells and hence often evokes severe side
effects [19].
The EGFR-GEP100-Arf6-AMAP1 pathway appears to
be cancer-specific, as earlier mentioned. To date, how-
ever, despite a number of studies on EGFR and its down-
stream signaling pathways, the Arf6 pathway has not
been analyzed in HNSCCs. This may be because previ-
ous gene expression profiling analyses on clinical sam-
ples of HNSCCs and other cancers have not nominated
this pathway to be correlated with poor prognosis and/
or poor survival, as also earlier mentioned. Protein levels
of Arf6 and AMAP1 do not correlate with their mRNA
levels in breast cancer cells. Such a lack of correlation
might not be specific to breast cancer cells, since we
found that mRNAs of both Arf6 and AMAP1 have long
5′-untranslated regions with relatively large free-energy
changes and hence are classified as typically 'weak-
mRNAs', that are neither immediately nor efficiently
translated into proteins on their own [29]. These proper-
ties of the AMAP1 and Arf6 mRNAs might have hin-
dered them from their previous identification, also in
studied on HNSCCs.
In this study, we successfully showed that expression
of the AMAP1 protein at high levels, as well as its co-
Figure 1 Immunohistochemical staining of EGFR (A), GEP100 (B), AMAP1 (C), and cortactin (D) in primary HNSCCs. Tissue sections were
immunostained with antibodies against each target protein, as indicated. Positive staining of the proteins is shown in a reddish-brown color. The
staining intensity of each protein in tumor cells was graded on a scale of 0–2, as described under Materials and methods. A representative figure
for each staining is shown. Bars, 100 μm.
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poor disease-free survival and poor overall survival of
HNSCC patients, while larger numbers of patients need
to be analyzed to further generalize this notion. We
propose that protein levels of AMAP1, together with
protein levels of EGFR, provide a simple and excellent
biomarker predictive for the recurrence and survivalof HNSCC patients under the current therapeutics.
The Arf6 pathway mediates the motile and invasive phe-
notypes of cancers. These phenotypes are thought to be
critical for their resistance to radiotherapy, in which the
tumor cells that survive radiation may escape from the
sites of radiation, that are hypoxemic and inflammatory
due to the radiation. Thus, combinations of AMAP1-
Figure 2 (See legend on next page.)
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Figure 2 Kaplan-Meier curves for the 5-year disease-free survival and overall survival of patients with HNSCCs expressing each single
protein. Patients were subclassified into the high-expression group and the low-expression group based on results of the immunostainings, as
described under Materials and methods. Kaplan-Meier curves were drawn with regard to the disease-free survival and the overall survival (A, C, E,
and G) of patients (B, D, F and H), by comparing the high-expression group and the low-expression group of each target protein, as indicated.
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improve the therapeutic effects against HNSCCs.
Conclusions
We propose that immunohistochemical staining of the
AMAP1 protein on its own, or together with staining of
the EGFR protein, provides a simple and reliable diagno-
sis that predicts the recurrence and survival of HNSCC
patients under the current therapeutics. Our identifica-
tion of these predictive biomarkers, together with our
previous findings on the coherent signaling pathway that
these biomarkers ultimately generate, namely the EGFR-
GEP100-Arf6-AMAP1-cortactin pathway, should be




Antibodies against the following proteins were purchased
from commercial sources: cortactin (CST, Lake Placid,
NY) and EGFR (TDL and 31G7 mAb, Nichirei, Tokyo).
Rabbit polyclonal antibodies against AMAP1 and GEP100
were as described previously [21,23]. These rabbit poly-
clonal antibodies were affinity-purified by use of each
corresponding peptide used for the immunization, and
their specificity on western blotting and the validity on
immunohistochemistry were carefully verified before
use [21-24,30].
Patients and samples
All clinical specimens were selected from patients with
primary tongue squamous cell carcinoma, who underwent
tongue resection at Hokkaido University Hospital between
March 1996 and March 2012, and were analyzed retro-
spectively. This study was approved by the Institutional
Review Board of Hokkaido University Hospital, Japan
(study number 012–0166). The requirement for written
consent was waived by this board in accordance with the
Ethical Guidelines for Clinical Studies of the Japanese
Ministry of Health, Labor and Welfare. Clinical stages
of the cancers were evaluated according to the 2002
International Union Against Cancer staging system.
Patient characteristics
The characteristics of and the treatment regimens for the
patients (n = 20; 15 men and 5 women) who underwent
primary surgical resection for HNSCC in the Departments
of Otolaryngology, and Head and Neck Surgery, HokkaidoUniversity Graduate School of Medicine (Sapporo, Japan)
are summarized in Table 1. The median age of the patients
was 60.7 years (range 31–84 years). The tumor site was
the oral cavity (tongue) in all patients. The clinical tumor
stage was T2 for 13 patients and T3 for 7 patients. Ten pa-
tients were node-positive and 10 were node-negative.
Pathological findings revealed that 61.4% (n = 12) of the
cancers were classified as well differentiated, 30.7% (n = 7)
as moderately differentiated and 7.9% (n = 1) as poorly
differentiated. Nine patients (45%) received radiation ther-
apy and three patients (15%) received chemotherapy prior
to surgery. The median follow–up for the 12 surviving pa-
tients was 65.5 months (range, 5–175 months).
Immunohistochemistry
The methods of immunohistochemical staining were as
described previously [21,23,30]. Briefly, immunohisto-
chemical staining was performed using 3 μm-thick
formalin-fixed paraffin-embedded sequential sections as
follows. Samples were first deparaffinized in xylene and
dehydrated in graded alcohols. After rinsing in TBS buffer
(25 mM Tris–HCl (pH 7.4), 137 mM NaCl, and 2.7 mM
KCl), the sections were processed for antigen retrieval in a
pepsin solution (Nichirei) at 37°C for 10 min (for EGFR)
in a 1 mM ethylenedyamine tetra-acetic acid (EDTA) re-
trieval solution (pH 9.0) (45211 Nichirei), at 95°C for 40
min (for AMAP1 and GEP100). Endogenous peroxidase
was then blocked by incubation in 0.3% H2O2-methanol
at room temperature for 10 min. After rinsing with TBS,
sections were then incubated with primary antibodies
against EGFR (1:50), AMAP1 (1:500) or GEP100 (1:100)
for 30 min, then with EnVisionTM (Dako, Tokyo) for 30
min, and finally with peroxidase-conjugated streptavidin
(Vector Labs, Burlingame, CA) for 50 min. After rinsing
in TBS, the coloring reaction was performed with DAB
(Dojin, Kumamoto) for 5 min. Each section was counter-
stained with hematoxylin. These processes were all per-
formed at room temperature.
Scoring
Immunohistochemical samples were scored by two in-
vestigators, which include one pathologist (K.C.H.). They
evaluated the staining of various proteins (EGFR,
GEP100, AMAP1, and cortactin) under a light micro-
scope at a magnification of × 200. The staining intensity
of each protein in tumor cells was graded on a scale of
0–2, in which no staining was scored as 0, weak staining
was scored as 1, and strong staining was scored as 2.
Figure 3 (See legend on next page.)
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Figure 3 Kaplan-Meier curves for the 5-year disease-free survival and overall survival of patients with HNSCCs expressing a
combination of each of the two different proteins. Patients were subclassified into the 'Homo' group and the 'Others'. The Homo group
consists of those expressing both target proteins at high levels (i.e., both belong to the high-expression groups), while Others consist of the rest
of them. Kaplan-Meier curves were drawn with regard to the disease-free survival (A, C, E, G and I) and the overall survival of patients (B, D, F,
H, J and L), by comparing the Homo group vs. the Others.
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specimen, and a proportional score was assigned (0 if
0%, 0.1-0.9 if 10–90%, and 1 if 100%). Proportional
scores were multiplied by the staining intensity to obtain
a final semi-quantitative H score. Median values of the
H score were chosen as the cut off point for distinguish-
ing between the low and high expression levels of each
protein [26].
Statistical analyses
Overall survival was calculated from the date of the sur-
gical treatment to the date of death or the most recent
follow-up. Disease-free survival was defined as the time
from the date of the surgical treatment to the date of the
first observation of disease progression, or relapse, or
death due to any cause. Overall survival and disease-free
survival were analyzed using the Kaplan-Meier method.
The calculated p-value was considered to be significant
when less than 0.05. These analyses were performed
using StatcelW software (OMS Ltd., Tokyo).
Abbreviations
HNSCCs: Head and neck squamous cell carcinomas; EGFR: Epidermal growth
factor receptor; GEF: Guanine nucleotide exchanging factor; PRKD2: Protein
kinase D2; TBS: Tries-buffered saline; DFS: Disease-free survival.
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